XML 47 R9.htm IDEA: XBRL DOCUMENT v3.25.0.1
Insider Trading Arrangements
 3 Months Ended
Dec. 31, 2024
shares
Trading Arrangements, by Individual  
Material Terms of Trading Arrangement

During the three months ended December 31, 2024, no director or officer adopted or terminated any Rule 10b5-1 trading arrangement or any non-Rule 10b5-1 trading arrangement (as such terms are defined pursuant to Item 408(a) of Regulation S-K), except as follows:

On December 30, 2024, Byron Robinson, Ph.D., our Chief Strategy Officer, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 238,000 shares of our common stock until August 31, 2025.

On December 30, 2024, Zachariah McIver, D.O., Ph.D., our Chief Medical Officer, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 76,587 shares of our common stock until April 1, 2026.

On December 30, 2024, Tommy DiRaimondo, Ph.D., our Chief Scientific Officer, modified an existing Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c). The modified trading arrangement terminates on August 29, 2025 and provides for the sale of up to 91,100 shares of our common stock.

In addition, our officers (as defined in Rule 16a-1(f) under the Exchange Act) have entered into sell-to-cover arrangements adopted pursuant to Rule 10b5-1 authorizing the pre-arranged sale of shares to satisfy our tax withholding obligations arising exclusively from the vesting of restricted stock units. The amount of shares to be sold to satisfy our tax withholding obligations under these arrangements is dependent on future events which cannot be known at this time, including the future trading price of our shares. The expiration date relating to these arrangements is dependent on future events which cannot be known at this time, including the final vesting date of the applicable shares of restricted stock and the officer’s termination of service.
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
Byron Robinson, Ph.D [Member]  
Trading Arrangements, by Individual  
Name Byron Robinson, Ph.D
Title Chief Strategy Officer
Rule 10b5-1 Arrangement Adopted true
Adoption Date December 30, 2024
Expiration Date August 31, 2025
Aggregate Available 238,000
Zachariah McIver, D.O Ph.D [Member]  
Trading Arrangements, by Individual  
Name Zachariah McIver, D.O., Ph.D
Title Chief Medical Officer
Rule 10b5-1 Arrangement Adopted true
Adoption Date December 30, 2024
Expiration Date April 1, 2026
Aggregate Available 76,587
Tommy DiRaimondo, Ph.D [Member]  
Trading Arrangements, by Individual  
Name Tommy DiRaimondo, Ph.D
Title Chief Scientific Officer
Rule 10b5-1 Arrangement Terminated true
Termination Date August 29, 2025
Aggregate Available 91,100
Modified Date December 30, 2024
Rule 10b51 Arr Modified [Flag] true